Category,VariableName,ExtractedValue,Notes
Study identifiers,study_id,AlMohamady_2016,Internal ID constructed as FirstAuthor_Year
Study identifiers,first_author,Al Mohamady,
Study identifiers,publication_year,2016,
Study identifiers,journal,International Journal of Fertility and Sterility,
Study identifiers,doi,,DOI not reported in article text provided
Study identifiers,country,Egypt,"Kasr El-Aini Hospital, Cairo University"
Study identifiers,setting,"Outpatient clinic and casualty department, Obstetrics and Gynecology, Kasr El-Aini Hospital",
Study identifiers,study_design,Prospective comparative case-control study,
Study identifiers,recruitment_period,March 2013–October 2013,
Study identifiers,funding_source,Not reported,
Study identifiers,registration_id,Not reported,
Eligibility & sample,sample_size_total,100,105 initially recruited; 5 dropped out; 100 analyzed
Eligibility & sample,n_tm,100,All had first-trimester threatened miscarriage
Eligibility & sample,n_miscarriage,20,Group 1
Eligibility & sample,n_ongoing,80,Group 2; continued to at least 20 weeks
Eligibility & sample,inclusion_criteria,"Women 20–40 years with singleton spontaneous pregnancy, 7–13 weeks gestation, vaginal bleeding/spotting, viable intrauterine pregnancy with visible gestational sac and cardiac activity on ultrasound; regular cycles with LMP correlating with ultrasound.",
Eligibility & sample,exclusion_criteria,"History of diabetes or thyroid disease; fibroids or adnexal masses; uterine malformations (e.g., hypoplastic or septate uterus); recurrent miscarriages; maternal diseases that increase CA-125 (chronic pelvic infection, endometriosis); abnormal dating scan (blighted ovum, missed miscarriage).",
Eligibility & sample,ga_range_included,7–13 weeks,Gestational age at recruitment
Eligibility & sample,maternal_age_range,20–40 years,
Baseline maternal,mean_maternal_age,,Not numerically reported; only that no significant difference between groups
Baseline maternal,parity_distribution,,Parity mentioned but not given numerically
Baseline maternal,prior_miscarriage_any_n,,Women with recurrent miscarriage history were excluded; exact counts not reported
Baseline maternal,assisted_conception_n,,Not reported
Presentation,ga_at_presentation_group1_mean_weeks,8.8,Group 1 miscarried; from Table 1
Presentation,ga_at_presentation_group2_mean_weeks,9.2,Group 2 continued; Table 1 P=0.304 (NS)
Presentation,bleeding_required,Yes,All presented with vaginal bleeding or spotting
Presentation,bleeding_severity,,Amount of bleeding assessed clinically but not quantified in categories in results
Presentation,pain_recorded,,Abdominal pain not explicitly reported
Ultrasound predictors,ultrasound_machine,"Accuvix (Medison, Korea)",4–7 MHz endovaginal probe
Ultrasound predictors,probe_frequency_mhz,4–7,Endovaginal
Ultrasound predictors,viable_iup_confirmed_definition,Visible gestational sac with living embryo verified by cardiac activity on real-time ultrasound,
Ultrasound predictors,gremium_ga_assessment_method,Gestational age assessed from LMP (preceded by 3 regular cycles) and correlated with ultrasound measurements,
Ultrasound predictors,gsd_group1_mean_mm,30.0,Gestational sac diameter (miscarried group)
Ultrasound predictors,gsd_group2_mean_mm,37.7,Gestational sac diameter (continued group); P=0.023
Ultrasound predictors,crl_group1_mean_mm,24.0,Crown–rump length (miscarried group); P=0.317 vs group 2
Ultrasound predictors,crl_group2_mean_mm,28.5,Crown–rump length (continued group)
Ultrasound predictors,fhr_group1_mean_bpm,122,Fetal heart rate (miscarried group)
Ultrasound predictors,fhr_group2_mean_bpm,156.9,Fetal heart rate (continued group); P<0.001
Ultrasound predictors,sch_present_group1_n,5,Presence of subchorionic hematoma in miscarried group (n=20)
Ultrasound predictors,sch_present_group2_n,2,Presence of subchorionic hematoma in continued group (n=80); P=0.002 overall
Ultrasound predictors,sch_size_measurement,,Presence/absence only; size and site not quantified
Biochemical markers,ca125_assay_type,"Direct chemiluminometric assay (ADVIA Centaur, Bayer Health Care Diagnostics, USA)",
Biochemical markers,ca125_unit,IU/ml,
Biochemical markers,ca125_group1_mean,54.28,Mean CA-125 in miscarried group ± SD 11.4 IU/ml
Biochemical markers,ca125_group1_sd,11.4,
Biochemical markers,ca125_group2_mean,18.81,Mean CA-125 in continued group ± SD 8.02 IU/ml
Biochemical markers,ca125_group2_sd,8.02,
Biochemical markers,progesterone_assay_type,"Direct chemiluminometric assay (ADVIA Centaur, Bayer Health Care Diagnostics, USA)",
Biochemical markers,progesterone_unit,ng/ml,
Biochemical markers,progesterone_group1_mean,8.7,Mean serum progesterone in miscarried group ± SD 1.85 ng/ml
Biochemical markers,progesterone_group1_sd,1.85,
Biochemical markers,progesterone_group2_mean,26.3,Mean serum progesterone in continued group ± SD 7.2 ng/ml
Biochemical markers,progesterone_group2_sd,7.2,
Biochemical markers,blood_sample_volume_ml,5,5 ml venous sample
Biochemical markers,sample_handling,Serum separated after clotting by centrifugation at 3000 rpm for 10 minutes; stored at -80°C until batch analysis,
Biochemical markers,correlation_ca125_progesterone_r,-0.716,"CA-125 vs progesterone, P<0.001"
Biochemical markers,correlation_ca125_fhr_r,-0.414,"CA-125 vs FHR, P<0.001"
Biochemical markers,correlation_progesterone_gsd_r,0.521,"Progesterone vs GSD, P<0.001"
Biochemical markers,correlation_progesterone_crl_r,0.407,"Progesterone vs CRL, P<0.001"
Biochemical markers,correlation_progesterone_fhr_r,0.363,"Progesterone vs FHR, P<0.001"
Outcomes,outcome_primary_definition,Miscarriage before 20 weeks vs continuation of pregnancy to at least 20 weeks,Follow-up until 20 weeks gestation
Outcomes,followup_end_ga_weeks,20,
Performance metrics,ca125_cutoff_main,31.2,IU/ml; threshold for predicting miscarriage
Performance metrics,ca125_sensitivity_main_cutoff,96.2,Percent
Performance metrics,ca125_specificity_main_cutoff,100,Percent
Performance metrics,ca125_overall_accuracy,99.4,Percent; as reported
Performance metrics,progesterone_cutoff_main,11.5,ng/ml; threshold for predicting miscarriage
Performance metrics,progesterone_sensitivity_main_cutoff,97.5,Percent
Performance metrics,progesterone_specificity_main_cutoff,100,Percent
Performance metrics,progesterone_overall_accuracy,99.8,Percent; as reported
Performance metrics,auc_ca125,,ROC used but AUC not numerically reported
Performance metrics,auc_progesterone,,ROC used but AUC not numerically reported
Study identifiers,study_id,Cao_2025,Internal ID constructed as FirstAuthor_Year
Study identifiers,first_author,Cao,Yurong Cao
Study identifiers,publication_year,2025,
Study identifiers,journal,PLOS One,
Study identifiers,doi,10.1371/journal.pone.0326384,
Study identifiers,country,"Multinational (Asia, Europe, Africa)","Included study populations: Asia, Europe, Africa"
Study identifiers,setting,Hospital-based threatened abortion populations from 13 primary studies,
Study identifiers,study_design,Systematic review and meta-analysis of prognostic accuracy,
Study identifiers,prisma_followed,Yes,Followed PRISMA 2020 guidelines
Study identifiers,prospero_registration_id,CRD42024600834,International Prospective Register of Systematic Reviews
Study identifiers,search_databases,Web of Science; Medline via PubMed; ScienceDirect; EMBASE; Geenmedical; Cochrane Library; Wiley,
Study identifiers,search_period,"Inception to May 30, 2024",
Study identifiers,search_terms,(serum cancer antigen125 OR serum CA125 OR CA125 OR CA-125) AND (threatened abortion OR threatened miscarriage OR pregnancy loss OR first trimester abortion OR first trimester pregnancy OR early pregnancy failure OR pregnancy outcome),
Study identifiers,funding_source,No specific funding,Authors reported no specific funding
Study identifiers,registration_id,CRD42024600834,Same as PROSPERO registration
Eligibility & sample,sample_size_total,1166,Total patients with threatened abortion across 13 included studies
Eligibility & sample,n_miscarriage,387,Total miscarriage cases across included studies
Eligibility & sample,n_ongoing,779,Patients with ongoing or normal pregnancy/delivery after follow-up
Eligibility & sample,number_of_included_studies,13,
Eligibility & sample,inclusion_criteria,"Patients with threatened abortion defined per ACOG: 5–20 weeks gestation with vaginal bleeding and/or abdominal pain, closed cervical os, intact membranes, viable intrauterine pregnancy with fetal cardiac activity on ultrasound; studies evaluating CA125 prognostic value for miscarriage with sensitivity and specificity available.",
Eligibility & sample,exclusion_criteria,"Case reports, conference abstracts, systematic reviews, animal experiments, letters; duplicate publications; studies without threatened abortion populations; studies without sensitivity/specificity data or with inconsistent data.",
Eligibility & sample,ga_range_included,5–20 weeks gestation,Threatened abortion defined before 20 weeks; included studies ranged roughly 5–19+6 weeks
Eligibility & sample,continents_distribution,Asia (1/13; 135 patients); Europe (4/13; 718 patients); Africa (8/13; 313 patients),
Outcomes,outcome_primary_definition,Miscarriage after presentation with threatened abortion versus ongoing pregnancy/normal delivery,"Miscarriage confirmed clinically, by ultrasound, or histopathology during follow-up"
Outcomes,followup_end_ga_weeks,,Follow-up deadlines varied (≤20 weeks vs >20 weeks) across studies; used as covariate in meta-regression
Outcomes,outcomes_extracted_per_study,"Sensitivity, specificity, TP, FP, TN, FN, miscarriage diagnosis and follow-up deadlines",
Biochemical markers,index_test,Serum CA125,Single biomarker as the prognostic index test
Biochemical markers,cutoff_range_across_studies,21–125 IU/mL,Europe: 43–125 IU/mL; Africa: 21–80 IU/mL; Asia: 55 U/mL
Biochemical markers,regional_cutoff_pattern,Higher optimal cut-offs in European studies; lower in African studies; Asia intermediate,
Performance metrics,pooled_sensitivity,0.89,Sensitivity 89% (95% CI 0.83–0.93)
Performance metrics,pooled_sensitivity_95ci,0.83–0.93,
Performance metrics,pooled_specificity,0.91,Specificity 91% (95% CI 0.84–0.95)
Performance metrics,pooled_specificity_95ci,0.84–0.95,
Performance metrics,pooled_plr,10.2,Positive likelihood ratio (95% CI 5.4–19.3)
Performance metrics,pooled_plr_95ci,5.4–19.3,
Performance metrics,pooled_nlr,0.13,Negative likelihood ratio (95% CI 0.08–0.19)
Performance metrics,pooled_nlr_95ci,0.08–0.19,
Performance metrics,pooled_dor,82,Diagnostic odds ratio (95% CI 31–212)
Performance metrics,pooled_dor_95ci,31–212,
Performance metrics,pooled_auc_sroc,0.95,AUC of SROC (95% CI 0.92–0.96)
Performance metrics,pooled_auc_95ci,0.92–0.96,
Performance metrics,threshold_effect_present,No,"Spearman correlation between log(SEN) and log(1-SPE) = -0.588, P = 0.044 (no threshold effect)"
Performance metrics,heterogeneity_sensitivity_i2,56.43,"χ² = 27.54, P = 0.01; random-effects model used"
Performance metrics,heterogeneity_specificity_i2,81.82,"χ² = 66.00, P = 0.00; high heterogeneity"
Performance metrics,meta_regression_covariates,Follow-up deadline (≤20 vs >20 weeks); sample size (≤100 vs >100); study population (Africa vs other continents),
Performance metrics,meta_regression_findings,Sample size and study population significantly explained heterogeneity; follow-up deadline did not (P = 0.11),
Performance metrics,publication_bias_assessment,No significant publication bias,Deek’s funnel plot P = 0.81 (symmetrical)
Risk of bias,risk_of_bias_tool,QUAPAS,Adaptation of QUADAS-2 for prognostic accuracy
Risk of bias,risk_of_bias_domains,Participants; index test; outcome; flow and timing; analysis,
Risk of bias,common_risk_of_bias_issues,Participant selection bias; population imbalance; variation in assay methods and management practices,
Risk of bias,grade_sensitivity,Moderate,Sensitivity downgraded due to participant bias and moderate heterogeneity
Risk of bias,grade_specificity,Low,Downgraded for risk of bias and substantial heterogeneity
Risk of bias,grade_plr,Low,"Downgraded for risk of bias, wide CI, and indirectness"
Risk of bias,grade_nlr,Low,Downgraded for risk of bias and imprecision
Risk of bias,grade_dor,Low,Downgraded for risk of bias and inconsistency (very wide CI)
Risk of bias,grade_auc,Low,Downgraded for risk of bias and indirectness
Study identifiers,study_id,Ku_2015,Internal ID constructed as FirstAuthor_Year
Study identifiers,first_author,Ku,Chee Wai Ku
Study identifiers,publication_year,2015,
Study identifiers,journal,Gynecological Endocrinology,
Study identifiers,doi,10.3109/09513590.2015.1031103,
Study identifiers,country,Singapore,Tertiary women’s hospital emergency unit in Singapore
Study identifiers,setting,Emergency unit of tertiary women’s hospital,Women presenting with threatened miscarriage
Study identifiers,study_design,Prospective cohort study,
Study identifiers,recruitment_period,,Not reported in the accessible text
Study identifiers,funding_source,Not reported,Declaration of interest notes no conflicts; funding not specified
Study identifiers,registration_id,,Study registration not reported
Eligibility & sample,sample_size_total,119,Prospective cohort of 119 women with threatened miscarriage
Eligibility & sample,n_tm,119,All participants had threatened miscarriage at 6–10 weeks
Eligibility & sample,n_miscarriage,30,30/119 (25.2%) had spontaneous miscarriage
Eligibility & sample,n_ongoing,89,119 - 30 = 89 ongoing pregnancies
Eligibility & sample,inclusion_criteria,Women presenting with threatened miscarriage between 6 and 10 weeks of gestation at a tertiary women’s hospital emergency unit; viable intrauterine pregnancy at presentation.,Detailed criteria not fully visible in web snapshot/PDF capture
Eligibility & sample,exclusion_criteria,,Not clearly visible in captured text
Eligibility & sample,ga_range_included,6–10 weeks,Gestation weeks 6 to 10 at presentation
Presentation,bleeding_required,Yes,Threatened miscarriage (vaginal bleeding with viable pregnancy)
Presentation,ga_at_presentation_range_weeks,6–10,As specified in abstract
Presentation,bleeding_severity,,Severity categories not visible in captured text
Presentation,pain_recorded,,Not clearly reported in accessible text
Biochemical markers,progesterone_used,Yes,Serum progesterone as primary biomarker
Biochemical markers,pibf_used,Yes,Progesterone-induced blocking factor (PIBF) evaluated alongside progesterone
Biochemical markers,progesterone_or_per_unit,0.91,OR per unit increase in serum progesterone (95% CI 0.88–0.94) associated with lower miscarriage risk
Biochemical markers,progesterone_or_95ci,0.88–0.94,
Biochemical markers,pibf_or_per_unit,0.99,OR per unit increase in PIBF (95% CI 0.98–0.99) associated with lower miscarriage risk
Biochemical markers,pibf_or_95ci,0.98–0.99,
Biochemical markers,progesterone_mean_levels,,Exact mean±SD progesterone levels by outcome group not visible in captured text
Biochemical markers,pibf_mean_levels,,Exact mean±SD PIBF levels not visible in captured text
Prediction model details,model_name,Ku_2015_risk_model,Label assigned for extraction purposes
Prediction model details,model_type,Logistic regression,Predictive models for probability of spontaneous miscarriage
Prediction model details,model_purpose,Multivariable clinical+biochemical model,To calculate probability of spontaneous miscarriage in TM
Prediction model details,predictors_in_model,Serum progesterone; maternal BMI; fetal heart rate,As described in abstract: progesterone together with maternal BMI and fetal heart rate
Prediction model details,feature_selection_method,,Specific selection strategy not visible in captured text
Prediction model details,handling_missing_data,,Not reported in accessible text
Prediction model details,internal_validation_method,,Any internal validation (bootstrapping/cross-validation) not visible in the captured pages
Prediction model details,external_validation,No,Single-centre derivation cohort only; no external validation reported in abstract
Prediction model details,model_presentation,Probability model described; details likely in full text,Abstract mentions proposed models; full regression equation not visible
Outcomes,outcome_primary_definition,Completed spontaneous miscarriage after presentation with threatened miscarriage,Spontaneous miscarriage vs ongoing pregnancy
Outcomes,followup_end_ga_weeks,,Exact follow-up endpoint not clearly visible in captured text
Performance metrics,auc_roc,,"If AUC reported, it is not visible in captured web/PDF snapshot"
Performance metrics,sensitivity_main_cutoff,,Sensitivity/specificity at chosen cut-offs not visible in current text
Performance metrics,specificity_main_cutoff,,
Study identifiers,study_id,Ku_2025,Internal ID constructed as FirstAuthor_Year
Study identifiers,first_author,Ku,Chee Wai Ku
Study identifiers,publication_year,2025,
Study identifiers,journal,Frontiers in Medicine,
Study identifiers,doi,10.3389/fmed.2025.1669594,
Study identifiers,country,Singapore,"KK Women’s and Children’s Hospital, Singapore"
Study identifiers,setting,Urgent O&G Center (UOGC) of KK Women’s and Children’s Hospital,Single-center tertiary women’s hospital
Study identifiers,study_design,Prospective cohort study,
Study identifiers,recruitment_period,6 October 2017–20 May 2023,
Study identifiers,strobe_used,Yes,Followed STROBE reporting guideline
Study identifiers,ethics_approval,SingHealth CIRB 2017/2638,
Study identifiers,funding_source,"Lien Foundation Optimizing Maternal and Child Health Program; National Medical Research Council, Ministry of Health, Singapore",
Study identifiers,registration_id,,Clinical trial registration not reported
Eligibility & sample,sample_size_total,1080,Total analyzed women with threatened miscarriage
Eligibility & sample,n_tm,1080,All had threatened miscarriage with viable IUP
Eligibility & sample,n_miscarriage,187,Miscarriage by 16 weeks’ gestation
Eligibility & sample,n_ongoing,893,Ongoing pregnancy at 16 weeks
Eligibility & sample,miscarriage_rate_percent,17.3,187/1080
Eligibility & sample,screened_total,1938,Women screened at UOGC
Eligibility & sample,excluded_n,584,Met one or more exclusion criteria at screening
Eligibility & sample,lost_to_followup_n,246,Lost to follow-up before 16 weeks
Eligibility & sample,unknown_fetal_pole_status_n,12,
Eligibility & sample,not_in_ga_range_n,13,GA outside 5–12 weeks by ultrasound
Eligibility & sample,inclusion_criteria,Women presenting with threatened miscarriage at 5–12 weeks’ gestation (per vaginal bleeding with intrauterine gestational sac and fetal pole) with single confirmed intrauterine pregnancy dated via transvaginal ultrasound.,
Eligibility & sample,exclusion_criteria,Received progestogens during current pregnancy; multiple gestations; IVF pregnancies; incomplete or missed miscarriage (CRL ≥7 mm without cardiac activity); pregnancy of unknown location; ectopic pregnancy; termination of pregnancy; no fetal pole present.,
Eligibility & sample,ga_range_included,5–12 weeks,Gestation by ultrasound at presentation
Baseline maternal,mean_maternal_age_all,31.0,"Mean age (years) for all, SD 4.44"
Baseline maternal,sd_maternal_age_all,4.44,
Baseline maternal,mean_maternal_age_ongoing,30.8,"Ongoing pregnancy group, SD 4.26"
Baseline maternal,sd_maternal_age_ongoing,4.26,
Baseline maternal,mean_maternal_age_miscarriage,31.7,"Miscarriage group, SD 5.17"
Baseline maternal,sd_maternal_age_miscarriage,5.17,
Baseline maternal,ethnicity_chinese_n,544,Chinese overall n (50.4%)
Baseline maternal,ethnicity_chinese_ongoing_n,455,
Baseline maternal,ethnicity_chinese_miscarriage_n,89,
Baseline maternal,ethnicity_malay_n,263,24.4% overall
Baseline maternal,ethnicity_malay_ongoing_n,217,
Baseline maternal,ethnicity_malay_miscarriage_n,46,
Baseline maternal,ethnicity_indian_n,136,12.6% overall
Baseline maternal,ethnicity_indian_ongoing_n,110,
Baseline maternal,ethnicity_indian_miscarriage_n,26,
Baseline maternal,ethnicity_others_n,136,12.6% overall; counts appear duplicated in table for Others
Baseline maternal,ethnicity_others_ongoing_n,110,As reported in table; potential typographical duplication
Baseline maternal,ethnicity_others_miscarriage_n,26,
Baseline maternal,bmi_underweight_n,52,"BMI <18.5 kg/m², 5.5% overall"
Baseline maternal,bmi_normal_n,498,"18.5–24.9 kg/m², 52.3% overall"
Baseline maternal,bmi_overweight_n,250,"25.0–29.9 kg/m², 26.3% overall"
Baseline maternal,bmi_obese_n,152,"≥30 kg/m², 16.0% overall"
Baseline maternal,prior_miscarriages_1_n,192,81.4% with 1 prior miscarriage among those with any prior miscarriages (row subtotal)
Baseline maternal,prior_miscarriages_ge2_n,44,18.6% with ≥2 prior miscarriages
Presentation,nausea_no_n,591,66.6% overall without nausea
Presentation,nausea_yes_n,296,33.4% overall with nausea
Presentation,nausea_no_ongoing_n,480,64.8%
Presentation,nausea_no_miscarriage_n,111,76.0%
Presentation,pain_no_n,652,61.4% overall without pain
Presentation,pain_yes_n,410,38.6% overall with pain
Presentation,pbac_0_n,25,PBAC score 0 (2.4%)
Presentation,pbac_1_n,867,81.6%
Presentation,pbac_2_n,24,2.3%
Presentation,pbac_3_n,6,0.6%
Presentation,smoker_no_n,177,93.2% of those with smoking data
Presentation,smoker_yes_n,13,6.8%; smoking data missing in n=890
Ultrasound predictors,ga_ultrasound_mean_all,7.28,"Mean GA by US (weeks), SD 1.71"
Ultrasound predictors,ga_ultrasound_sd_all,1.71,
Ultrasound predictors,ga_ultrasound_mean_ongoing,7.51,SD 1.77
Ultrasound predictors,ga_ultrasound_sd_ongoing,1.77,
Ultrasound predictors,ga_ultrasound_mean_miscarriage,6.20,SD 0.77
Ultrasound predictors,ga_ultrasound_sd_miscarriage,0.77,
Ultrasound predictors,fetal_heart_absent_n,151,14.0% overall
Ultrasound predictors,fetal_heart_present_n,929,86.0% overall
Ultrasound predictors,fetal_heart_absent_ongoing_n,62,6.9% in ongoing group
Ultrasound predictors,fetal_heart_absent_miscarriage_n,89,47.6% in miscarriage group
Ultrasound predictors,ultrasound_machine,Philips HS50,Transvaginal sonography device
Ultrasound predictors,ga_assessment_method,CRL (crown–rump length),GA determined via CRL
Ultrasound predictors,msd_measurement_method,Mean of three orthogonal planes (mm),
Ultrasound predictors,pregnancy_failure_criterion_msd,MSD ≥25 mm with no fetal pole,Diagnostic criterion for early pregnancy failure
Biochemical markers,progesterone_assay_type,"ARCHITECT progesterone kit (Abbott, Ireland)",Measured in KKH clinical laboratory
Biochemical markers,progesterone_unit,nmol/L,
Biochemical markers,low_progesterone_cutoff,35,<35 nmol/L defined as low/high-risk threshold
Biochemical markers,low_progesterone_n,198,18.4% overall with serum progesterone <35 nmol/L
Biochemical markers,low_progesterone_ongoing_n,61,6.9% of ongoing pregnancies
Biochemical markers,low_progesterone_miscarriage_n,137,73.3% of miscarriages
Biochemical markers,progesterone_treatment_given_n,257,23.8% overall received progesterone at UOGC
Biochemical markers,progesterone_treatment_ongoing_n,121,13.5% ongoing
Biochemical markers,progesterone_treatment_miscarriage_n,136,72.7% miscarriage group
Biochemical markers,sample_processing,"Maternal blood in plain tubes; centrifuged 10 min at 3,000 g within 2 h of collection",
Prediction model details,model1_description,Clinical + biochemical + radiological factors,"Maternal age, absence of nausea, number of miscarriages, low progesterone, GA, absence of fetal heart"
Prediction model details,model1_auroc,0.90,95% CI 0.87–0.93
Prediction model details,model1_aic,496.1,
Prediction model details,model2_description,"Reduced model (clinical + biochemical + radiological): maternal age, low progesterone, GA, absence of fetal heart",
Prediction model details,model2_auroc,0.90,95% CI 0.87–0.93
Prediction model details,model2_aic,495.2,
Prediction model details,model3_description,Clinical + biochemical (no ultrasound),
Prediction model details,model3_auroc,0.85,95% CI 0.82–0.89
Prediction model details,model3_aic,562.8,
Prediction model details,model4_description,Clinical + radiological (no progesterone),
Prediction model details,model4_auroc,0.80,95% CI 0.77–0.84
Prediction model details,model4_aic,706.0,
Prediction model details,model5_description,Clinical factors only,
Prediction model details,model5_auroc,0.57,95% CI 0.53–0.62
Prediction model details,model5_aic,887.5,
Prediction model details,model1_or_maternal_age,1.05,aOR (95% CI 1.00–1.11) per year
Prediction model details,model1_or_low_progesterone,26.3,aOR (95% CI 16.6–41.6) for progesterone <35 nmol/L
Prediction model details,model1_or_ga,0.57,aOR (95% CI 0.45–0.73) per week
Prediction model details,model1_or_absent_fetal_heart,3.91,aOR (95% CI 2.28–6.71)
Prediction model details,model2_or_maternal_age,1.05,aOR (95% CI 1.00–1.11)
Prediction model details,model2_or_low_progesterone,26.3,aOR (95% CI 16.6–41.5)
Prediction model details,model2_or_ga,0.57,aOR (95% CI 0.45–0.73)
Prediction model details,model2_or_absent_fetal_heart,4.05,aOR (95% CI 2.37–6.92)
Prediction model details,risk_score_equation,Score = 2*(age ≥40 years) + 3*(progesterone <35 nmol/L) + 1*(GA <6.36 weeks) + 2*(absence of fetal heart),Total scores 0–8
Prediction model details,risk_score_cutoff_ga_weeks,6.36,Cut-off for GA from ROC analysis
Prediction model details,risk_score_or_age_ge40,5.11,"aOR (95% CI 1.8–14.48), score 2"
Prediction model details,risk_score_or_prog_lt35,28.42,"aOR (95% CI 17.98–44.91), score 3"
Prediction model details,risk_score_or_ga_lt6_36,2.86,"aOR (95% CI 1.77–4.64), score 1"
Prediction model details,risk_score_or_no_fetal_heart,4.53,"aOR (95% CI 2.62–7.86), score 2"
Prediction model details,risk_score_low_group_range,0–2,Miscarriage 4.7% (38/811)
Prediction model details,risk_score_medium_group_range,3–5,Miscarriage 39.6% (74/187)
Prediction model details,risk_score_high_group_range,6–8,Miscarriage 97.4% (75/77)
Performance metrics,risk_score_auroc,0.82,AUROC for risk-score model
Performance metrics,risk_score_sensitivity_cutoff2,0.80,At optimal cut-off score 2
Performance metrics,risk_score_specificity_cutoff2,0.84,
Performance metrics,risk_score_ppv_cutoff2,0.51,
Performance metrics,risk_score_npv_cutoff2,0.95,
Performance metrics,risk_score_cv_auroc_mean,0.89,Average AUROC from 10-fold cross-validation
Performance metrics,risk_score_cv_auroc_95ci,0.85–0.92,"From 2,000 bootstrap replications"
Risk of bias,multiple_imputation_used,Yes,Chained equations with fully conditional specification
Risk of bias,firth_correction_used,Yes,Used in logistic regression to address separation
Risk of bias,missing_data_fraction,<0.05,Less than 0.05% missing in final model (5/1080)
Risk of bias,software_used,"SAS 9.4; Stata 18; R (mice, pROC)",
Study identifiers,study_id,Lek_2017,Internal ID constructed as FirstAuthor_Year
Study identifiers,first_author,Lek,Sze Min Lek
Study identifiers,publication_year,2017,
Study identifiers,journal,BMC Pregnancy and Childbirth,
Study identifiers,doi,10.1186/s12884-017-1261-4,
Study identifiers,country,Singapore,"KK Women’s and Children’s Hospital, Singapore"
Study identifiers,setting,24-h Women’s Clinic at KK Women’s and Children’s Hospital (tertiary hospital emergency unit for women),
Study identifiers,study_design,Prospective cohort study (validation cohort with comparison to prior pilot cohort),
Study identifiers,recruitment_period,September 2013–June 2015,
Study identifiers,funding_source,SingHealth Foundation Research Grant Call,
Study identifiers,ethics_approval,SingHealth CIRB 2013/320/D,
Study identifiers,registration_id,,Trial registration not reported
Eligibility & sample,sample_size_recruited_validation,360,Validation cohort recruited 360 women
Eligibility & sample,lost_to_followup_n,11,Lost to follow-up before 16 weeks
Eligibility & sample,withdrawn_termination_n,3,Withdrew due to induced termination of pregnancy
Eligibility & sample,sample_size_total,346,Validation cohort with outcome data analyzed
Eligibility & sample,n_tm,346,All had threatened miscarriage at 6–10 weeks
Eligibility & sample,n_miscarriage,70,20.2% experienced spontaneous miscarriage prior to week 16 in validation cohort
Eligibility & sample,n_ongoing,276,Ongoing pregnancy at 16 weeks (validation cohort)
Eligibility & sample,pilot_sample_size_total,119,Pilot cohort described in earlier Ku et al. study
Eligibility & sample,pilot_n_miscarriage,30,25.2% miscarried in pilot cohort
Eligibility & sample,pilot_n_ongoing,89,Ongoing in pilot cohort
Eligibility & sample,inclusion_criteria,Pregnant women aged ≥21 years with single intrauterine pregnancy between gestation weeks 6–10 (confirmed and dated by ultrasonography) presenting with pregnancy-related per vagina bleeding at the KKH 24-h Women’s Clinic.,
Eligibility & sample,exclusion_criteria,"Women with previous episodes of per vagina bleeding or treated with progesterone for previous per vagina bleeding in the current pregnancy; women diagnosed with inevitable miscarriage, missed miscarriage, blighted ovum, or planned termination of pregnancy.",
Eligibility & sample,ga_range_included,6–10 weeks,Gestational age at recruitment by ultrasound
Biochemical markers,progesterone_assay_type,"ARCHITECT progesterone kit (Abbott, Ireland)",Measured in KKH clinical laboratory
Biochemical markers,progesterone_unit,nmol/L,
Biochemical markers,sample_handling,Maternal blood collected in plain tubes; centrifuged 10 min at 3000 g within 2 h of collection.,
Biochemical markers,progesterone_mean_ongoing_pilot,59.8,"Mean serum progesterone (nmol/L) in pilot cohort, ongoing pregnancy at 16 weeks; SD 23.5"
Biochemical markers,progesterone_sd_ongoing_pilot,23.5,
Biochemical markers,progesterone_mean_ongoing_validation,60.3,"Mean serum progesterone (nmol/L) in validation cohort, ongoing pregnancy; SD 22.7"
Biochemical markers,progesterone_sd_ongoing_validation,22.7,
Biochemical markers,progesterone_mean_miscarriage_pilot,26.4,"Mean serum progesterone (nmol/L) in pilot cohort, miscarriage; SD 17.1"
Biochemical markers,progesterone_sd_miscarriage_pilot,17.1,
Biochemical markers,progesterone_mean_miscarriage_validation,31.4,"Mean serum progesterone (nmol/L) in validation cohort, miscarriage; SD 20.1"
Biochemical markers,progesterone_sd_miscarriage_validation,20.1,
Baseline maternal,mean_maternal_age_ongoing_validation,30.3,"Mean maternal age (years) in validation cohort, ongoing pregnancies; SD 4.10"
Baseline maternal,sd_maternal_age_ongoing_validation,4.10,
Baseline maternal,mean_maternal_age_miscarriage_validation,31.6,"Mean maternal age (years) in validation cohort, miscarriages; SD 5.22"
Baseline maternal,sd_maternal_age_miscarriage_validation,5.22,
Baseline maternal,ga_at_recruitment_mean_ongoing_validation,7.48,"Gestational age at recruitment (weeks) in validation cohort, ongoing pregnancies; SD 1.47"
Baseline maternal,ga_at_recruitment_sd_ongoing_validation,1.47,
Baseline maternal,ga_at_recruitment_mean_miscarriage_validation,6.63,"Gestational age at recruitment (weeks) in validation cohort, miscarriages; SD 1.06"
Baseline maternal,ga_at_recruitment_sd_miscarriage_validation,1.06,
Baseline maternal,previous_miscarriage_ongoing_validation_percent,24.0,"Previous miscarriage (%) in validation cohort, ongoing pregnancies"
Baseline maternal,previous_miscarriage_miscarriage_validation_percent,22.9,"Previous miscarriage (%) in validation cohort, miscarriage group"
Baseline maternal,bmi_mean_ongoing_validation,22.9,Mean BMI (kg/m²) ongoing pregnancies; SD 4.29
Baseline maternal,bmi_sd_ongoing_validation,4.29,
Baseline maternal,bmi_mean_miscarriage_validation,23.6,Mean BMI (kg/m²) miscarriages; SD 4.81
Baseline maternal,bmi_sd_miscarriage_validation,4.81,
Ultrasound predictors,fetal_pole_present_ongoing_validation_percent,100,"Presence of fetal pole (%) in validation cohort, ongoing pregnancies"
Ultrasound predictors,fetal_pole_present_miscarriage_validation_percent,100,"Presence of fetal pole (%) in validation cohort, miscarriages"
Ultrasound predictors,fetal_heart_present_ongoing_validation_percent,95.6,"Presence of fetal heart (%) in validation cohort, ongoing pregnancies"
Ultrasound predictors,fetal_heart_present_miscarriage_validation_percent,70.0,"Presence of fetal heart (%) in validation cohort, miscarriages"
Outcomes,outcome_primary_definition,Spontaneous miscarriage by the 16th week of gestation vs ongoing pregnancy at 16 weeks,"Miscarriage defined by uterine evacuation after inevitable or incomplete miscarriage, or complete miscarriage with an empty uterus"
Outcomes,followup_end_ga_weeks,16,All participants contacted at 16 weeks to verify pregnancy status
Prediction model details,logit_pilot_intercept_b0,2.8439,"Intercept for pilot cohort logistic regression (outcome = miscarriage, predictor = progesterone)"
Prediction model details,logit_pilot_progesterone_b1,-0.0971,Coefficient for progesterone (nmol/L) in pilot cohort
Prediction model details,logit_validation_intercept_b0,2.1063,Intercept for validation cohort logistic regression
Prediction model details,logit_validation_progesterone_b1,-0.0782,Coefficient for progesterone (nmol/L) in validation cohort
Performance metrics,auc_pilot,0.89,AUC (95% CI 0.81–0.97) for progesterone in pilot cohort
Performance metrics,auc_pilot_95ci,0.81–0.97,
Performance metrics,auc_validation,0.83,AUC (95% CI 0.77–0.89) for progesterone in validation cohort
Performance metrics,auc_validation_95ci,0.77–0.89,
Performance metrics,auc_difference_pilot_validation,0.06,Difference in AUC (pilot - validation); 95% CI -0.04–0.15; p = 0.267
Biochemical markers,progesterone_cutoff_main,35,nmol/L; threshold for high risk of miscarriage before 16 weeks
Performance metrics,pilot_sensitivity_cutoff35,0.767,Sensitivity 76.7% (95% CI 0.577–0.901); 23/30
Performance metrics,pilot_specificity_cutoff35,0.888,Specificity 88.8% (95% CI 0.803–0.945); 79/89
Performance metrics,pilot_ppv_cutoff35,0.697,PPV 69.7% (95% CI 0.513–0.844); 23/33
Performance metrics,pilot_npv_cutoff35,0.919,NPV 91.9% (95% CI 0.839–0.967); 79/86
Performance metrics,pilot_lr_positive,6.82,LR+ at <35 nmol/L
Performance metrics,pilot_lr_negative,0.26,LR- at <35 nmol/L
Performance metrics,validation_sensitivity_cutoff35,0.657,Sensitivity 65.7% (95% CI 0.534–0.767); 46/70
Performance metrics,validation_specificity_cutoff35,0.920,Specificity 92.0% (95% CI 0.881–0.949); 253/275 (text also refers to 254 TN in accuracy section)
Performance metrics,validation_ppv_cutoff35,0.677,PPV 67.7% (95% CI 0.552–0.785); 46/68
Performance metrics,validation_npv_cutoff35,0.913,NPV 91.3% (95% CI 0.874–0.944); 253/277
Performance metrics,validation_lr_positive,8.21,LR+ at <35 nmol/L
Performance metrics,validation_lr_negative,0.37,LR- at <35 nmol/L
Performance metrics,validation_accuracy_cutoff35,0.87,Accuracy 300/346 (95% CI 0.83–0.90)
Performance metrics,validation_tp_cutoff35,46,True positives (<35 nmol/L and miscarried)
Performance metrics,validation_tn_cutoff35,254,True negatives (≥35 nmol/L and ongoing); slight inconsistency with 253/275 in Table 2
Performance metrics,validation_fp_cutoff35,24,False positives (<35 nmol/L but ongoing)
Performance metrics,validation_fn_cutoff35,22,False negatives (≥35 nmol/L but miscarried); counts yield 68 miscarriages vs 70 stated; minor internal discrepancy
Study identifiers,study_id,Mishoe_2020,Internal ID constructed as FirstAuthor_Year; Systematic Review Snapshot based on Pillai RN et al. 2018 meta-analysis
Study identifiers,first_author,Mishoe,Jonathan M. Mishoe
Study identifiers,publication_year,2020,
Study identifiers,journal,Annals of Emergency Medicine,
Study identifiers,doi,10.1016/j.annemergmed.2019.02.014,From CrossRef link in PDF
Study identifiers,country,Multinational,Systematic review/meta-analysis of studies from multiple countries
Study identifiers,setting,Emergency departments and early pregnancy assessment units,Women with early pregnancy and threatened abortion
Study identifiers,study_design,Systematic review snapshot summarising diagnostic accuracy meta-analysis,"Snapshot of Pillai RN et al., Eur J Obstet Gynecol Reprod Biol. 2018;220:122–131"
Study identifiers,primary_source_citation,"Pillai RN, Konje JC, Richardson M, et al. Prediction of miscarriage in women with viable intrauterine pregnancy—a systematic review and diagnostic accuracy meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2018;220:122–131.",
Eligibility & sample,number_of_included_studies_qualitative,27,27 studies met inclusion criteria for qualitative analysis
Eligibility & sample,number_of_included_studies_quantitative,18,18 studies included in quantitative analysis
Eligibility & sample,patient_population_definition,"Pregnant women with viable intrauterine pregnancy between 6 weeks and 15 weeks + 6 days of gestation, with or without vaginal bleeding.",
Eligibility & sample,inclusion_criteria,"Prospective cohort studies using combinations or individual ultrasonographic markers to predict miscarriage in women with a viable intrauterine pregnancy and gestational age 6 to 15+6 weeks, with or without vaginal bleeding.",
Eligibility & sample,exclusion_criteria,Studies using Doppler criteria alone; studies including women with uterine malformations or medical conditions contributing to miscarriage; studies without clear differentiation between viable pregnancy and miscarriage at baseline; unspecified exclusion criteria; variable sonographer expertise.,Summarised from risk-of-bias discussion
Ultrasound predictors,index_tests_evaluated,Fetal pulse rate (bradycardia); crown-rump length; intrauterine hematoma; difference between mean gestational sac diameter and crown-rump length; abnormal yolk sac.,
Ultrasound predictors,fetal_bradycardia_definition,Fetal pulse rate ≤ 110 beats/min,Identified as most accurate cut-off to predict miscarriage
Ultrasound predictors,ongoing_pregnancy_protective_fhr_7w,>134,Fetal pulse rate >134 beats/min at 7 weeks predictive of ongoing pregnancy in two studies
Ultrasound predictors,ongoing_pregnancy_protective_fhr_8w,>158,Fetal pulse rate >158 beats/min at 8 weeks predictive of ongoing pregnancy in two studies
Outcomes,outcome_primary_definition,Progression to miscarriage after initial ultrasound with viable intrauterine pregnancy.,
Performance metrics,fhr_bradycardia_all_studies_n,10,Number of studies reporting fetal bradycardia in asymptomatic and vaginal bleeding populations
Performance metrics,fhr_bradycardia_all_patients_n,1762,Total number of women in these 10 studies
Performance metrics,fhr_bradycardia_all_sensitivity,68.41,Sensitivity % (95% CI 43.62–85.84) for miscarriage when fetal pulse rate ≤ 110 bpm in asymptomatic and VB combined
Performance metrics,fhr_bradycardia_all_sensitivity_95ci,43.62–85.84,
Performance metrics,fhr_bradycardia_all_specificity,97.84,Specificity % (95% CI 94.50–99.17)
Performance metrics,fhr_bradycardia_all_specificity_95ci,94.50–99.17,
Performance metrics,fhr_bradycardia_all_plr,31.73,Positive likelihood ratio (95% CI 12.78–78.75)
Performance metrics,fhr_bradycardia_all_plr_95ci,12.78–78.75,
Performance metrics,fhr_bradycardia_all_nlr,0.32,Negative likelihood ratio (95% CI 0.16–0.65)
Performance metrics,fhr_bradycardia_all_nlr_95ci,0.16–0.65,
Performance metrics,fhr_bradycardia_vbonly_studies_n,5,Studies including only women with vaginal bleeding
Performance metrics,fhr_bradycardia_vbonly_patients_n,771,Total women in these 5 studies
Performance metrics,fhr_bradycardia_vbonly_sensitivity,84.18,Sensitivity % (95% CI 42.02–97.50)
Performance metrics,fhr_bradycardia_vbonly_sensitivity_95ci,42.02–97.50,
Performance metrics,fhr_bradycardia_vbonly_specificity,95.68,Specificity % (95% CI 87.76–98.56)
Performance metrics,fhr_bradycardia_vbonly_specificity_95ci,87.76–98.56,
Performance metrics,fhr_bradycardia_vbonly_plr,19.51,Positive likelihood ratio (95% CI 5.44–69.84)
Performance metrics,fhr_bradycardia_vbonly_plr_95ci,5.44–69.84,
Performance metrics,fhr_bradycardia_vbonly_nlr,0.16,Negative likelihood ratio (95% CI 0.03–0.91)
Performance metrics,fhr_bradycardia_vbonly_nlr_95ci,0.03–0.91,
Performance metrics,crl_studies_n,5,"Number of studies analysing CRL (1,136 women)"
Performance metrics,crl_patients_n,1136,
Performance metrics,crl_sensitivity,59.81,Sensitivity % (95% CI 48.78–69.93)
Performance metrics,crl_sensitivity_95ci,48.78–69.93,
Performance metrics,crl_specificity,55.68,Specificity % (95% CI 39.95–70.35)
Performance metrics,crl_specificity_95ci,39.95–70.35,
Performance metrics,crl_plr,1.34,Positive likelihood ratio (95% CI 0.91–2.00)
Performance metrics,crl_plr_95ci,0.91–2.00,
Performance metrics,crl_nlr,0.72,Negative likelihood ratio (95% CI 0.49–1.06)
Performance metrics,crl_nlr_95ci,0.49–1.06,
Performance metrics,iuh_sensitivity_range,17–92,Sensitivity % range for intrauterine hematoma in women with vaginal bleeding and confirmed fetal viability
Performance metrics,iuh_specificity_range,17–83,Specificity % range
Performance metrics,msd_crl_discrepancy_studies_n,2,Two studies with 349 women
Performance metrics,msd_crl_discrepancy_patients_n,349,
Performance metrics,msd_crl_sensitivity_range,39–96,Sensitivity % range for difference in mean gestational sac diameter and CRL
Performance metrics,msd_crl_specificity_range,73–88,Specificity % range
Performance metrics,abnormal_yolk_sac_studies_n,3,Three studies with 605 asymptomatic women
Performance metrics,abnormal_yolk_sac_patients_n,605,
Performance metrics,abnormal_yolk_sac_sensitivity_range,17–69,Sensitivity % range
Performance metrics,abnormal_yolk_sac_specificity_range,79–99,Specificity % range
Risk of bias,risk_of_bias_tool,QUADAS-2,Quality Assessment of Diagnostic Accuracy Studies–2 used for methodological assessment
Risk of bias,common_sources_of_bias,Inclusion of women with uterine malformations or medical conditions contributing to miscarriage; unclear exclusion criteria; lack of clear baseline distinction between viable pregnancy and miscarriage; variable sonographer expertise.,
Study identifiers,study_id,Pillai_2016,Internal ID constructed as FirstAuthor_Year
Study identifiers,first_author,Pillai,Rekha N. Pillai
Study identifiers,publication_year,2016,
Study identifiers,journal,Human Reproduction Update,
Study identifiers,article_title,Role of serum biomarkers in the prediction of outcome in women with threatened miscarriage: a systematic review and diagnostic accuracy meta-analysis,
Study identifiers,doi,10.1093/humupd/dmv054,
Study identifiers,country,Multinational,Systematic review/meta-analysis including studies from multiple countries
Study identifiers,study_design,Systematic review and diagnostic accuracy meta-analysis of prospective cohort studies,
Study identifiers,timeframe_of_search,Up to June 2015,"Medline (1946–June 2015), Embase (1980–June 2015), Cochrane Library, ClinicalTrials.gov, WHO ICTRP, LILAC, OpenGrey"
Eligibility & sample,eligibility_study_design,Prospective studies evaluating serum biochemical markers to predict outcome in women with threatened miscarriage,
Eligibility & sample,eligibility_ga_range_weeks,5–23,Gestational age window for inclusion
Eligibility & sample,eligibility_tm_definition,"Vaginal bleeding with or without lower abdominal pain, closed internal os on cervical examination, and ultrasound-confirmed viable intrauterine pregnancy","Based on Saraswat et al. 2010 and NICE CG 154, 2012"
Eligibility & sample,exclusion_criteria_overall,"Retrospective design, case reports/series, reviews; no 5–23 week window; infertility or recurrent miscarriage cohorts; pregnancy of unknown location; ovulation induction or exogenous hormones; treatments for prevention of miscarriage; non-English language without translation",
Eligibility & sample,n_identified_initial_search,6820,6727 from electronic search + 93 from other sources
Eligibility & sample,n_screened_fulltext,35,Manuscripts reviewed in detail
Eligibility & sample,n_included_qualitative,19,Studies included in qualitative synthesis
Eligibility & sample,n_included_quantitative,15,Studies included in diagnostic accuracy meta-analysis
Eligibility & sample,n_total_women_meta,1263,Total women across 15 meta-analysed studies
Biochemical markers,biomarkers_evaluated,"Serum hCG (intact and β-hCG), progesterone, estradiol, pregnancy-associated plasma protein A (PAPP-A), cancer antigen 125 (CA 125)","Plus single-study markers HPL, AFP, SP1, PZP, plasma renin activity/substrate, SHBG, inhibin A, activin A, follistatin, estriol"
Biochemical markers,hcg_studies_n,8,Total hCG or β-hCG studies included in quantitative analysis
Biochemical markers,hcg_total_women,584,
Biochemical markers,progesterone_studies_n,6,Serum progesterone studies
Biochemical markers,progesterone_total_women,481,
Biochemical markers,estradiol_studies_n,4,
Biochemical markers,estradiol_total_women,244,
Biochemical markers,pappa_studies_n,3,
Biochemical markers,pappa_total_women,236,
Biochemical markers,ca125_studies_n,7,
Biochemical markers,ca125_total_women,648,
Outcomes,outcome_primary_definition,Prediction of subsequent miscarriage in women with threatened miscarriage and viable intrauterine pregnancy at baseline,"Miscarriage confirmed clinically, by ultrasound, or histopathology"
Statistical methods,software_meta_analysis,Review Manager 5.3 (Cochrane),
Statistical methods,meta_analysis_model,Hierarchical summary receiver operating characteristic (HSROC) modelling for biomarkers with ≥4 studies,"Rutter & Gatsonis HSROC, empirical Bayes estimates of study-specific sensitivity and specificity"
Statistical methods,between_study_heterogeneity,"Considerable heterogeneity, reflected in wide prediction regions on HSROC plots, especially for progesterone and estradiol",
Performance metrics,hcg_summary_sensitivity_percent,44,Sensitivity % (95% CI 17–75)
Performance metrics,hcg_summary_sensitivity_95ci,17–75,
Performance metrics,hcg_summary_specificity_percent,86,Specificity % (95% CI 80–91)
Performance metrics,hcg_summary_specificity_95ci,80–91,
Performance metrics,hcg_summary_plr,3.37,Positive likelihood ratio (95% CI 1.98–5.74)
Performance metrics,hcg_summary_plr_95ci,1.98–5.74,
Performance metrics,hcg_summary_nlr,0.63,Negative likelihood ratio (95% CI 0.36–1.11)
Performance metrics,hcg_summary_nlr_95ci,0.36–1.11,
Performance metrics,progesterone_summary_sensitivity_percent,30,Sensitivity % (95% CI 2–87)
Performance metrics,progesterone_summary_sensitivity_95ci,2–87,
Performance metrics,progesterone_summary_specificity_percent,86,Specificity % (95% CI 78–91)
Performance metrics,progesterone_summary_specificity_95ci,78–91,
Performance metrics,progesterone_summary_plr,2.24,Positive likelihood ratio (95% CI 0.32–15.80)
Performance metrics,progesterone_summary_plr_95ci,0.32–15.80,
Performance metrics,progesterone_summary_nlr,0.81,Negative likelihood ratio (95% CI 0.35–1.86)
Performance metrics,progesterone_summary_nlr_95ci,0.35–1.86,
Performance metrics,estradiol_summary_sensitivity_percent,45,Sensitivity % (95% CI 6–90)
Performance metrics,estradiol_summary_sensitivity_95ci,6–90,
Performance metrics,estradiol_summary_specificity_percent,87,Specificity % (95% CI 81–92)
Performance metrics,estradiol_summary_specificity_95ci,81–92,
Performance metrics,estradiol_summary_plr,3.72,Positive likelihood ratio (95% CI 1.01–13.71)
Performance metrics,estradiol_summary_plr_95ci,1.01–13.71,
Performance metrics,estradiol_summary_nlr,0.62,Negative likelihood ratio (95% CI 0.20–1.84)
Performance metrics,estradiol_summary_nlr_95ci,0.20–1.84,
Performance metrics,ca125_summary_sensitivity_percent,91,Sensitivity % (95% CI 83–94)
Performance metrics,ca125_summary_sensitivity_95ci,83–94,
Performance metrics,ca125_summary_specificity_percent,90,Specificity % (95% CI 79–93)
Performance metrics,ca125_summary_specificity_95ci,79–93,
Performance metrics,ca125_summary_plr,7.86,Positive likelihood ratio (95% CI 4.23–14.60)
Performance metrics,ca125_summary_plr_95ci,4.23–14.60,
Performance metrics,ca125_summary_nlr,0.10,Negative likelihood ratio (95% CI 0.05–0.20)
Performance metrics,ca125_summary_nlr_95ci,0.05–0.20,
Performance metrics,ca125_inverse_nlr,9.31,Inverse of negative likelihood ratio; 95% CI 5.0–17.1 (indicative value of test for identifying pregnancies likely to continue)
Performance metrics,pappa_sensitivity_range_percent,25–64,Sensitivity % range across 3 studies
Performance metrics,pappa_specificity_range_percent,88–94,Specificity % range across 3 studies
Risk of bias,risk_of_bias_tool,QUADAS-2,"Four domains: patient selection, index test, reference standard, flow and timing"
Risk of bias,common_bias_patient_selection,"Four studies did not specify exclusion criteria; some mixed populations (e.g. broader GA, other early pregnancy complications)",
Risk of bias,common_bias_index_test,Most studies did not prespecify biomarker cut-off levels; cut-offs often selected post hoc,
Risk of bias,common_bias_reference_standard,Outcome sometimes determined by telephone interview or case note review rather than standardized ultrasound/histology,
Risk of bias,common_bias_flow_timing,Not always clear whether women were followed up to at least 23 weeks; potential for incomplete ascertainment of miscarriage,
Study identifiers,study_id,Pillai_2018,Internal ID constructed as FirstAuthor_Year
Study identifiers,first_author,Pillai,Rekha N. Pillai
Study identifiers,publication_year,2018,
Study identifiers,journal,European Journal of Obstetrics & Gynecology and Reproductive Biology,
Study identifiers,article_title,Prediction of miscarriage in women with viable intrauterine pregnancy—A systematic review and diagnostic accuracy meta-analysis,
Study identifiers,doi,10.1016/j.ejogrb.2017.10.024,
Study identifiers,country,Multinational,Systematic review/meta-analysis of ultrasound-based prognostic markers
Study identifiers,study_design,Systematic review and diagnostic accuracy meta-analysis of prospective cohort studies,
Study identifiers,protocol_registration,PROSPERO CRD42016046470,
Study identifiers,timeframe_of_search,Medline 1946–June 2017; Embase 1980–June 2017; CINAHL 1981–June 2017; Cochrane Library,
Eligibility & sample,patient_population_definition,"Women with viable intrauterine pregnancy between 6 and 15+6 weeks’ gestation, with or without vaginal bleeding, undergoing ultrasound",
Eligibility & sample,inclusion_criteria,Prospective cohort studies evaluating ultrasound and/or combination markers to predict miscarriage in women with viable intrauterine pregnancy within 6–15+6 weeks’ gestation.,
Eligibility & sample,exclusion_criteria,Retrospective studies; studies without clear definition of viable intrauterine pregnancy at baseline; lack of separate data for viable pregnancies; non-ultrasound markers only; non-human or non-pregnancy studies.,Summarised from methods text
Eligibility & sample,n_identified_initial_search,4094,Records identified through database searching
Eligibility & sample,n_additional_records,46,Additional records identified through other sources
Eligibility & sample,n_screened_fulltext,27,Studies assessed for eligibility (qualitative)
Eligibility & sample,n_included_qualitative,27,Included in qualitative synthesis
Eligibility & sample,n_included_quantitative,18,Included in quantitative meta-analysis
Eligibility & sample,n_total_women_meta,5584,Total number of women in meta-analysed studies
Ultrasound predictors,ultrasound_markers_evaluated,Fetal heart rate (bradycardia or tachycardia); crown–rump length; intrauterine hematoma; difference between mean gestational sac diameter and crown–rump length; yolk sac morphology and size.,
Ultrasound predictors,fetal_bradycardia_definition,Fetal heart rate ≤ 110 beats/min,Identified as optimal cut-off based on plot of FHR cut-off versus log diagnostic odds ratio
Ultrasound predictors,protective_fhr_7weeks,>134,Fetal heart rate >134 bpm at 7 weeks associated with ongoing pregnancy in two studies
Ultrasound predictors,protective_fhr_8weeks,>158,Fetal heart rate >158 bpm at 8 weeks associated with ongoing pregnancy in two studies
Outcomes,outcome_primary_definition,Progression to miscarriage after index ultrasound with viable intrauterine pregnancy,
Performance metrics,fhr_bradycardia_all_studies_n,10,Studies included for fetal bradycardia across asymptomatic and VB populations
Performance metrics,fhr_bradycardia_all_patients_n,1762,
Performance metrics,fhr_bradycardia_all_sensitivity,68.41,Sensitivity % (95% CI 43.62–85.84)
Performance metrics,fhr_bradycardia_all_sensitivity_95ci,43.62–85.84,
Performance metrics,fhr_bradycardia_all_specificity,97.84,Specificity % (95% CI 94.50–99.17)
Performance metrics,fhr_bradycardia_all_specificity_95ci,94.50–99.17,
Performance metrics,fhr_bradycardia_all_plr,31.73,Positive likelihood ratio (95% CI 12.78–78.75)
Performance metrics,fhr_bradycardia_all_plr_95ci,12.78–78.75,
Performance metrics,fhr_bradycardia_all_nlr,0.32,Negative likelihood ratio (95% CI 0.16–0.65)
Performance metrics,fhr_bradycardia_all_nlr_95ci,0.16–0.65,
Performance metrics,fhr_bradycardia_vbonly_studies_n,5,Threatened miscarriage subgroup
Performance metrics,fhr_bradycardia_vbonly_patients_n,771,
Performance metrics,fhr_bradycardia_vbonly_sensitivity,84.18,Sensitivity % (95% CI 42.02–97.50)
Performance metrics,fhr_bradycardia_vbonly_sensitivity_95ci,42.02–97.50,
Performance metrics,fhr_bradycardia_vbonly_specificity,95.68,Specificity % (95% CI 87.76–98.56)
Performance metrics,fhr_bradycardia_vbonly_specificity_95ci,87.76–98.56,
Performance metrics,fhr_bradycardia_vbonly_plr,19.51,Positive likelihood ratio (95% CI 5.44–69.84)
Performance metrics,fhr_bradycardia_vbonly_plr_95ci,5.44–69.84,
Performance metrics,fhr_bradycardia_vbonly_nlr,0.16,Negative likelihood ratio (95% CI 0.03–0.91)
Performance metrics,fhr_bradycardia_vbonly_nlr_95ci,0.03–0.91,
Performance metrics,crl_studies_n,5,Number of CRL studies
Performance metrics,crl_patients_n,1136,
Performance metrics,crl_sensitivity,59.81,Sensitivity % (95% CI 48.78–69.93)
Performance metrics,crl_sensitivity_95ci,48.78–69.93,
Performance metrics,crl_specificity,55.68,Specificity % (95% CI 39.95–70.35)
Performance metrics,crl_specificity_95ci,39.95–70.35,
Performance metrics,crl_plr,1.34,Positive likelihood ratio (95% CI 0.91–2.00)
Performance metrics,crl_plr_95ci,0.91–2.00,
Performance metrics,crl_nlr,0.72,Negative likelihood ratio (95% CI 0.49–1.06)
Performance metrics,crl_nlr_95ci,0.49–1.06,
Performance metrics,iuh_sensitivity_range,17–92,Sensitivity % range for intrauterine hematoma
Performance metrics,iuh_specificity_range,17–83,Specificity % range
Performance metrics,msd_crl_discrepancy_studies_n,2,Difference between mean gestational sac diameter and CRL
Performance metrics,msd_crl_discrepancy_patients_n,349,
Performance metrics,msd_crl_sensitivity_range,39–96,Sensitivity % range
Performance metrics,msd_crl_specificity_range,73–88,Specificity % range
Performance metrics,abnormal_yolk_sac_studies_n,3,Ultrasound yolk sac morphology/size
Performance metrics,abnormal_yolk_sac_patients_n,605,
Performance metrics,abnormal_yolk_sac_sensitivity_range,17–69,Sensitivity % range
Performance metrics,abnormal_yolk_sac_specificity_range,79–99,Specificity % range
Risk of bias,risk_of_bias_tool,QUADAS-2,Used to assess methodological quality
Risk of bias,common_sources_of_bias,Inclusion of women with uterine malformations or medical conditions contributing to miscarriage; unclear exclusion criteria; sonographer expertise not always reported; variable follow-up duration.,Summarised from risk-of-bias domain discussion
Study identifiers,study_id,Sammut_2025,Internal ID constructed as FirstAuthor_Year
Study identifiers,first_author,Sammut,Lara Sammut
Study identifiers,publication_year,2025,
Study identifiers,journal,Radiography,
Study identifiers,article_title,Predicting first-trimester pregnancy outcome in threatened miscarriage: A comparison of a multivariate logistic regression and machine learning models,
Study identifiers,doi,10.1016/j.radi.2025.103159,
Study identifiers,country,Malta,"Single-centre study at Mater Dei Hospital, Malta"
Study identifiers,institutions,"University of Malta; Mater Dei Hospital; University of the West of England, Bristol",
Study identifiers,study_design,Prospective cohort study with multivariate logistic regression and random forest models,
Study identifiers,study_period,January 2023 – June 2024,
Eligibility & sample,tm_definition,First-trimester vaginal bleeding before 20 weeks with closed cervix and detectable fetal cardiac activity on ultrasound,
Eligibility & sample,ga_range_weeks,5+0 to 12+6,Gestational age at recruitment
Eligibility & sample,population,Women with viable singleton intrauterine pregnancies presenting with symptoms of threatened miscarriage,
Eligibility & sample,inclusion_criteria,Viable singleton intrauterine pregnancy 5+0–12+6 weeks; symptoms of threatened miscarriage; consent to participate,
Eligibility & sample,exclusion_criteria,Non-viable pregnancies; multiple gestations; ectopic and molar pregnancies,
Eligibility & sample,n_total_recruited,118,Total TM cases recruited
Eligibility & sample,n_live_birth,91,77% live birth
Eligibility & sample,n_pregnancy_loss,27,23% pregnancy loss
Eligibility & sample,age_group_counts,14–19 years: 3 (5%); 20–34 years: 46 (78%); 35–46 years: 10 (17%),
Eligibility & sample,sample_size_rationale,"Minimum required to build predictive model with up to eight predictors, each correlated at ≥0.35 with outcome",Based on Bland 2009 and Machin 2018 sample size texts
Predictors – ultrasound,us_predictors,"Fetal heart rate (FHR); mean gestational sac diameter (MGSD); crown-rump length (CRL); cervical length; mean amniotic sac diameter (MASD); trophoblast thickness (TT); yolk sac parameters (diameter, wall thickness, morphology); mean corpus luteum diameter and location; presence, size and location of intrauterine haematoma; uterine fibroids",
Predictors – ultrasound,us_measurement_details,"All scans performed by the same practitioner and equipment; MASD, TT and yolk sac measurements based on previously published methodologies",
Predictors – biochemical,bc_predictors,β-hCG; progesterone; placental growth factor (PlGF); soluble fms-like tyrosine kinase-1 (sFlt-1); sFlt-1:PlGF ratio,
Predictors – biochemical,bc_assay_details,Blood samples via venipuncture; analysed using standard clinical assays in hospital laboratory,
Predictors – clinical,clinical_predictors,Maternal age; BMI; bleeding volume (Pictorial Blood Assessment Chart); pain intensity; ethnicity; paternal age; educational attainment; employment status,
Outcomes,primary_outcome,Pregnancy outcome (live birth vs pregnancy loss) followed to term,"Outcome ascertained from hospital records, supplemented by telephone follow-up"
Correlation analysis,spearman_rho_progesterone,-0.47,Strongest negative correlation with pregnancy loss (P < 0.05)
Correlation analysis,spearman_rho_mgsd,-0.43,P < 0.05
Correlation analysis,spearman_rho_bhcg,-0.40,β-hCG x1000 IU/L; P < 0.05
Correlation analysis,spearman_rho_fhr,-0.35,P < 0.05
Correlation analysis,spearman_rho_crl,-0.31,P < 0.05
Correlation analysis,spearman_rho_cervical_length,-0.26,P < 0.05
Correlation analysis,spearman_rho_masd,-0.25,P < 0.05
Correlation analysis,spearman_rho_tt,-0.23,P < 0.05
Correlation analysis,spearman_rho_sflt1_plgf_ratio,-0.19,P < 0.05
Correlation analysis,spearman_rho_maternal_age,0.33,Positive correlation with pregnancy loss; P < 0.05
Univariate OR,or_progesterone,0.926,95% CI 0.889–0.958; P < 0.001; per 1 ng/mL increase
Univariate OR,or_fhr,0.969,95% CI 0.952–0.983; P < 0.001; per 1 bpm increase
Univariate OR,or_mgsd,0.906,95% CI 0.857–0.948; P < 0.001; per 1 mm increase
Univariate OR,or_bhcg,0.966,95% CI 0.946–0.983; P < 0.001; per 1000 IU/L increase
Univariate OR,or_cervical_length,0.908,95% CI 0.838–0.973; P < 0.05; per 1 mm increase
Univariate OR,or_masd,0.962,95% CI 0.930–0.991; P < 0.05; per 1 mm increase
Univariate OR,or_crl,0.953,95% CI 0.912–0.988; P < 0.05; per 1 mm increase
Univariate OR,or_sflt1_plgf_ratio,0.983,95% CI 0.965–0.998; P < 0.05
Univariate OR,or_tt,0.849,95% CI 0.706–0.984; P < 0.05; per 1 mm increase
Univariate OR,or_age_14_19_vs_20_34,12.545,95% CI 1.113–283.886; P < 0.05
Univariate OR,or_age_35_46_vs_20_34,4.182,95% CI 1.666–10.817; P < 0.05
Multivariable MLR,mlr_final_predictors,Progesterone; cervical length; MGSD; trophoblast thickness (TT); sFlt-1:PlGF ratio; maternal age 35–46 years; FHR × MGSD interaction; FHR,Final terms after backward stepwise selection
Multivariable MLR,mlr_or_progesterone_iqr,0.059,"95% CI 0.01–0.249; P < 0.001; 1-IQR increase, IQR = 24.85 ng/mL"
Multivariable MLR,mlr_or_cervical_length_iqr,0.356,"95% CI 0.123–0.834; P < 0.05; 1-IQR increase, IQR = 10.10 mm"
Multivariable MLR,mlr_or_mgsd_iqr,0.188,"95% CI 0.032–0.884; P < 0.05; 1-IQR increase, IQR = 20.22 mm"
Multivariable MLR,mlr_or_tt_iqr,4.179,"95% CI 1.217–16.468; P < 0.05; 1-IQR increase, IQR = 3.68 mm"
Multivariable MLR,mlr_or_sflt1_plgf_iqr,0.217,"95% CI 0.034–0.83; P < 0.05; 1-IQR increase, IQR = 37.92"
Multivariable MLR,mlr_or_age_35_46_vs_20_34,6.832,95% CI 1.628–35.862; P < 0.05
Multivariable MLR,mlr_or_fhr_mgsd_interaction_iqr,5.036,95% CI 1.13–27.919; P < 0.05; interaction term
Multivariable MLR,mlr_or_fhr_iqr,2.229,95% CI 0.664–8.92; P = 0.216; retained despite non-significance; IQR = 47.25 bpm
Multivariable MLR,mlr_intercept_or,0.007,95% CI 0.001–0.045; P < 0.001
Multivariable MLR,mlr_logit_equation,L = 21.9002 – 0.0681×FHR – 0.1622×CervicalL – 0.7595×MGSD + 0.4103×TT – 0.1099×Progesterone – 0.0713×(sFlt-1:PlGF) + 0.0041×FHR×MGSD + 2.3995×M_age35–46yrs,p = e^L / (1 + e^L)
Model performance – MLR,mlr_auc,0.89,Area under ROC; reported for training data and consistent with overall performance
Model performance – MLR,mlr_accuracy,82.7,Overall accuracy %
Model performance – MLR,mlr_sensitivity_at_0_326,0.80,At probability threshold 0.326
Model performance – MLR,mlr_specificity_at_0_326,0.80,At probability threshold 0.326
Model performance – MLR,mlr_sensitivity_high_thresh,0.90,At threshold 0.67; specificity decreases to 0.57
Model performance – MLR,mlr_specificity_high_thresh,0.57,At threshold 0.67
Model performance – MLR,mlr_ppv,0.55,Positive predictive value
Model performance – MLR,mlr_npv,0.90,Negative predictive value
Model performance – RF,rf_accuracy,93.1,Overall accuracy %
Model performance – RF,rf_auc_training,0.99,Training set AUC
Model performance – RF,rf_auc_testing,0.968,Testing set AUC
Model performance – RF,rf_threshold,0.242,Probability threshold selected for RF
Model performance – RF,rf_sensitivity_at_0_242,1.0,On testing data
Model performance – RF,rf_specificity_at_0_242,0.80,On testing data
Model performance – RF,rf_ppv,0.88,Positive predictive value
Model performance – RF,rf_npv,1.0,Negative predictive value
Model performance – comparison,training_confusion_summary,"On training data, RF produced one additional false positive compared with MLR; otherwise similar performance",
Model performance – comparison,testing_confusion_summary,"On testing data, RF had one false positive and no false negatives; MLR had three false positives and two false negatives",
Risk of bias / limitations,limitations_sample_size,Relatively small dataset (118 participants); cross-validation and larger samples needed for generalisability,
Risk of bias / limitations,limitations_overfitting,Very high RF sensitivity and NPV may partly reflect small sample size despite tuning to reduce overfitting,
Study identifiers,study_id,Shaamash_2020,Internal ID constructed as FirstAuthor_Year
Study identifiers,first_author,Shaamash,
Study identifiers,publication_year,2020,
Study identifiers,journal,Journal of Ultrasound in Medicine,
Study identifiers,doi,10.1002/jum.15282,
Study identifiers,country,Egypt (Assiut College of Medicine),Inferred from author affiliation mentioned in article acknowledgments
Study identifiers,setting,Single-center hospital-based cohort of women with first-trimester threatened miscarriage,Prospective observational study
Study identifiers,study_design,Prospective observational cohort,Described as prospective observational study
Study identifiers,recruitment_period,Not clearly stated in excerpt,Recruitment dates not visible in available text
Study identifiers,funding_source,Not reported,
Population & eligibility,inclusion_criteria,Women with first-trimester threatened miscarriage (vaginal bleeding with a viable intrauterine pregnancy) between ≥6–12 weeks’ gestation,From Methods: 241 patients with threatened miscarriage (≥6–12 weeks) had a single clinical and US evaluation
Population & eligibility,exclusion_criteria,Not fully described in available text,Likely excluded non-viable or non-intrauterine pregnancies; details not visible in excerpt
Population & eligibility,gestational_age_range_weeks,≥6–12,From abstract (≥6–12 weeks’ gestation)
Population & eligibility,n_recruited,241,241 patients with threatened miscarriage recruited
Population & eligibility,n_completed,233,233 patients completed follow-up to 28 weeks or miscarriage
Population & eligibility,n_continued_28w,193,193 pregnancies continued up to 28 weeks’ gestation
Population & eligibility,n_miscarriage_28w,40,40 miscarried before 28 weeks (17.1%)
Population & eligibility,miscarriage_rate_percent,17.1,40 of 233 completed pregnancies miscarried
Outcomes,primary_outcome,Pregnancy continuation up to 28 weeks (yes/no),Objective: predict pregnancy continuation up to 28 weeks in first-trimester threatened miscarriage
Outcomes,outcome_definition_miscarriage,Miscarriage before 28 weeks’ gestation following index presentation with threatened miscarriage,As reported in abstract: 40 miscarried (17.1%) before 28 weeks
Clinical predictors,clinical_predictors_list,Bleeding severity (spotting/mild bleeding) and progesterone treatment,Abstract: spotting/mild bleeding episodes and progesterone treatment were the clinical predictors of fetal viability
Clinical predictors,bleeding_severity_predictor,Spotting/mild bleeding associated with higher chance of fetal viability compared with heavier bleeding,Summarized from conclusion that spotting/mild bleeding predicted viability
Clinical predictors,progesterone_treatment_predictor,Use of progesterone treatment identified as a predictor of fetal viability,From abstract/conclusions
Ultrasound predictors,us_predictors_list,"Embryonic/fetal heart rate (E/FHR), crown-rump length (CRL), gestational sac diameter (GSD), and a combined ultrasound triad (E/FHR + CRL + GSD)",From results/conclusions
Ultrasound predictors,efhr_best_single_predictor,Yes,E/FHR described as the best single ultrasound predictor of fetal viability
Ultrasound predictors,efhr_specificity_single_marker_percent,95.3,Specificity of E/FHR as single ultrasound predictor
Ultrasound predictors,efhr_ppv_single_marker_percent,97.2,Positive predictive value of E/FHR as single ultrasound predictor
Ultrasound predictors,triad_components,"E/FHR, crown-rump length (CRL), gestational sac diameter (GSD)",First-trimester ultrasound triad of fetal viability
Ultrasound predictors,triad_cutoff_efhr_bpm,>113,E/FHR >113 beats per minute used in triad
Ultrasound predictors,triad_cutoff_crl_mm,>19.9,CRL >19.9 mm used in triad
Ultrasound predictors,triad_cutoff_gsd_mm,>27.3,GSD >27.3 mm used in triad
Ultrasound predictors,triad_specificity_percent,98,Specificity of first-trimester ultrasound triad of fetal viability
Ultrasound predictors,triad_ppv_percent,99,Positive predictive value of first-trimester ultrasound triad of fetal viability
Interpretation & counseling,clinical_counseling_implications,"Presence of E/FHR >113 bpm or the full ultrasound triad after a single scan provides a simple, measurable and effective predictor of pregnancy continuation up to 28 weeks; may reduce need for repeated emergency follow-up scans.",From conclusions: triad can improve counseling and decrease repeated emergency follow-up scans but does not replace routine scheduled scans
Risk of bias,risk_of_bias_overall,Unclear to moderate,Prospective single-center cohort with complete follow-up reported for 233/241; detailed information on blinding and handling of missing data not visible in excerpt
